Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.

  title={Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.},
  author={Ignatius Y. S. Tang and Donna S. Cox and Kruti N Patel and Bharathi V Reddy and Linda Nahlik and Sharon A Trevino and P. Terrence Murray},
  journal={The Annals of pharmacotherapy},
  volume={39 2},
BACKGROUND Argatroban, a direct thrombin inhibitor, is an effective anticoagulant for patients who have heparin-induced thrombocytopenia (HIT). Anticoagulation is usually required for renal replacement therapy (RRT). OBJECTIVE To prospectively evaluate the pharmacokinetics, pharmacodynamics, and safety of argatroban during RRT in hospitalized patients with or at risk for HIT. METHODS Five patients with known or suspected HIT underwent hemodialysis (n = 4) or continuous venovenous… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 27 extracted citations

Continuous Renal Replacement Therapy (CRRT)

Modelling and Control of Dialysis Systems • 2013
View 2 Excerpts
Highly Influenced

4Ts scoring with hemofiltration or hemodialysis clotting

Journal of Clinical Monitoring and Computing • 2014
View 1 Excerpt

Development and implementation of a nurse-driven, sliding-scale nomogram for bivalirudin in the management of heparin-induced thrombocytopenia.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2013

Similar Papers

Loading similar papers…